JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis
Executive Summary
Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.
You may also be interested in...
AbbVie May Be Poised For An Oral RA Smack Down
Upadacitinib hit the primary endpoints in the first of six Phase III studies in rheumatoid arthritis, as well as several important secondary endpoints. Continued success in Phase III will position the candidate well in the race to market with Lilly.
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.
Window Shopping: Rheumatoid Arthritis Biosimilars On Show At ACR
Clinicians in the US can’t buy in to anti-TNF biosimilars yet, but wave of equivalence data featured at American College of Rheumatology meeting gives them a chance to evaluate products before they hit the market.